JAZZ vs SCM · P/E 1988, rev $2.28B vs P/E 10, rev $97.8M
Jazz Pharmaceuticals PLC (JAZZ) versus Stellus Capital Investment (SCM) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Stellus Capital Investment (SCM) is a asset management company listed on NYSE.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported SCM revenue for 2025-12-31 was $97.8M. Net income was $27.0M. Revenue was down 2.1% from 2024-12-31 to 2025-12-31. SCM currently screens at market cap $244.6M and trailing P/E 10.2.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. SCM currently screens at market cap $244.6M and trailing P/E 10.2.
Not investment advice. Open the JAZZ and SCM stock pages for the full models.
Not investment advice.